Alizyme is the latest UK biotechnology company to seek a listing on the London Stock Exchange. The firm is floating on London's Alternative Investment Market with the aim of raising between L12 and 15 million ($18.4-$23.1 million). The flotation will give the firm a market capitalization of L20-L30 million.
The Cambridge-based firm focuses on the treatment and management of obesity and gastrointestinal disorders, and is building a product pipeline by a combination of inward licensing and in-house R&D. It will take products through to the end of Phase II clinical trials then license them out. The firm has already established a number of research or licensing agreements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze